Large Menopause Study Finds Abrupt Lab Changes Around the Final Period

On October 12, 2026, Nature Medicine published a Weizmann Institute-led study reporting abrupt shifts in multiple laboratory measures around women’s final menstrual period.

How does this update the gradual-change picture?

The gradual-change picture challenged by the researchers describes menopause-related physiological changes as a slow progression. Their findings suggest that this account is incomplete for several laboratory measures. Some changes appeared to cluster around the final menstrual period rather than unfold steadily across midlife.

This shifts the focus from reproductive hormones alone toward a wider set of health measures. For women following changes in their menstrual cycles, the study adds another dimension to the transition: what may be happening in laboratory results alongside changes in periods.

What did the analysis find?

According to the Weizmann Institute, researchers led by Uri Alon analyzed more than 300 million laboratory results from over one million women in the United States and Israel. They used data collected between 1999 and 2024. The scale allowed researchers to examine patterns across many types of tests rather than focus on a single hormone or health measure.

The institute’s account describes several findings:

• The analysis combined different sources of health data. These included the U.S. National Health and Nutrition Examination Survey and records from Israel’s Clalit health organization. Together they provided the material for examining how laboratory patterns related to the timing of menopause.
• Abrupt changes appeared across many test types. In the U.S. analysis, 52 of 90 laboratory-test types showed statistically significant abrupt changes. That finding challenges the idea that every measured physiological change around menopause follows a gradual course.
• The findings extended beyond reproductive hormones. Reported areas included sex hormones and measures related to bone health. Liver and kidney measures also featured, alongside blood chemistry and blood fats such as cholesterol.
• The comparison with men showed a different pattern. The institute reported that researchers did not find equivalent abrupt changes in men of similar ages. This comparison adds context to the timing of the changes observed in women.
• Hormone therapy users showed smaller shifts in many measures. Women receiving menopausal hormone therapy, or MHT, had less pronounced changes particularly in measures related to bone and liver and kidney function. This was a separate comparison within the analysis.

Taken together, these findings place the final menstrual period within a broader physiological picture. The research question is no longer only how reproductive hormones change. It also concerns how the timing of menopause relates to patterns across other health measures.

Did some hormone changes begin much earlier?

Yes. The expert-reaction summary published by Scimex described accelerated changes in several sex hormones more than a decade before the final menstrual period:

• Anti-Müllerian hormone declined more rapidly around 15 years beforehand.
• Estradiol declined more rapidly around 12 years beforehand.
• Follicle-stimulating hormone rose more rapidly around 14 years beforehand.

This part of the analysis adds a longer timescale to the findings around the final period. The study described both earlier changes in reproductive hormones and more concentrated shifts in other laboratory measures near menopause.

Those are related findings rather than competing descriptions. The transition can have an extended hormonal background while some measured changes appear more concentrated around the final menstrual period. That is a more useful reading of the research than choosing between a wholly gradual transition and a wholly sudden one.

How should the ‘cliff’ interpretation be read?

ABC’s reporting included Australian experts who urged caution about the study’s interpretation. The main boundaries belong together because they affect how the findings translate into personal health decisions:

• These are population patterns rather than an individual timetable. The analysis used pre-existing data and self-reported information about last menstrual periods. It reconstructed patterns across women; it did not establish that every woman experiences an identical change on the day of her final period. The “cliff” metaphor should be read in that population-level context.
• Laboratory shifts should not be relabelled as organ damage. The researchers reported changes in measures related to bone and liver and kidney function. Reading those findings as proof that menopause damages these organs would go beyond the evidence. The clinical meaning of a particular result belongs in an individual assessment.
• The MHT comparison does not establish a treatment effect. ABC reported that healthier women may be more likely to use MHT. Users and non-users may therefore have differed before treatment. The study was not a randomized trial, so it cannot establish that MHT caused the smaller shifts. Whether treatment timing affects particular outcomes remains a research question.
• The hormone findings are not a personal menopause clock. ABC noted that large fluctuations during perimenopause limit the use of hormone measurements to pinpoint an individual woman’s timing. A pattern identified across a population does not turn a hormone result into a reliable countdown.
• The study did not establish a universal screening schedule. Its findings support discussing appropriate preventive care. They do not specify a testing timetable or a standard set of investigations for every woman.

These boundaries leave a practical message: use the research to widen the health conversation rather than treat its most dramatic metaphor as a forecast.

What might a midlife health discussion cover?

ABC reported that endocrinologist Ada Cheung recommended discussing bone health and cholesterol around menopause, together with blood pressure and blood sugar. She also advised consulting a GP in one’s 40s about symptoms and bone and heart health, including whether hormone therapy is suitable.

That advice provides a useful framework for a conversation shaped by medical history and personal risk factors. The focus is not on requesting every measure mentioned in the research. It is on identifying which questions matter for the woman attending the appointment.

• Bone health: Which aspects of personal history make bone health relevant now? This keeps the discussion connected to the individual rather than to the size or prominence of the study. Bone-related measures were part of the reported findings and bone health was part of Cheung’s advice.
• Heart and metabolic health: Which checks are appropriate for cholesterol and blood pressure or blood sugar? These are the areas Cheung highlighted in ABC’s report. They provide a concrete starting point for discussing preventive health rather than leaving the conversation at a broad concern about menopause.
• Symptoms and existing results: Which concerns may relate to the hormonal transition and which need a broader explanation? The research is a reason to raise questions, not a reason to assume that a particular symptom or laboratory result is caused by menopause. Keeping that distinction clear protects the wider health assessment.
• Hormone therapy: Is MHT suitable in light of the woman’s symptoms and medical history? This keeps the treatment discussion anchored in personal care. The study’s comparison can be part of the conversation without becoming the sole reason for a treatment decision.

For readers thinking about heart health during the menopausal transition, this is a useful distinction between research and care. Research identifies a pattern worth investigating. A clinical conversation connects that pattern with the person’s circumstances and the decisions actually available to her.

The same perspective belongs in a wider view of life after menopause. The value of this analysis is not that it supplies a single explanation for midlife health. It gives women and clinicians more specific questions to discuss about timing and appropriate preventive attention.

How might this change clinical practice?

The most useful clinical legacy of this study would be earlier conversations about bone and heart health, grounded in each woman’s history and risks.

How Refemina helps

Choosing which menopause findings merit a personal health conversation calls for the kind of research-led explanation Refemina publishes. Its coverage addresses uncertainty about hormonal and nonhormonal causes while connecting physical changes with strength and confidence, helping readers understand evidence without reducing every midlife concern to hormones or a single answer.

Explore Resources

Sources

1. Menopause: More Than a Slow Change, It's a Sudden Shift Across the Body
2. Is there a 'cliff-like' decline at menopause? Australian experts unconvinced
3. EXPERT REACTION: A physiological 'cliff': sudden body changes at menopause